BankingBusiness

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

  • Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
  • Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
  • The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
  • Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
  • The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
  • Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)
Previous article
Swift: Passes on €50 million one-time discount
Next article
Added Health: Raises Over £1M
Laura M
Laura M
Laura is a financial reporter, editor, and researcher with a particular interest in fintech innovation, capital markets, and the evolving global banking landscape.

You May Also Like

FinTech

Revolut Strengthens Presence with Indian Hiring Spree

The financial technology company seeks to expand its team in India.Highlights: Revolut is launching a significant hiring campaign...
FinTech

Visa Strengthens Subscription Management Service for Businesses

New solutions aim to simplify recurring payment management for companies.Highlights: Visa has launched a new subscription management service.The...
FinTech

Mastercard to Sell Nets Payments Unit Following $3.2 Billion Acquisition

The divestment follows Mastercard's strategic review of its portfolio.Highlights: Mastercard is set to sell its Nets payments unit.The...
FinTech

Mastercard Seeks to Offload Payments Unit It Acquired for $32 Billion

The proposed sale comes as Mastercard re-evaluates its payments strategy.Highlights: Mastercard aims to sell its payments unit, originally...